whytestocks Wednesday, 11/04/20 08:30:22 PM Re: None Post # of 2551 JUST IN: $ATNM 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML - 70% of patients achieving remission were MRD-negative with remissions and MRD negativity reported in all dose cohorts - Data to be pr... Got this from ATNM - 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML @whytestocks